Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00372
|
|||||
| Drug Name |
Sofosbuvir
|
|||||
| Synonyms |
HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Chronic hepatitis C infection [ICD11: 1E51.1] | Approved | [1] | |||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H29FN3O9P
|
|||||
| Canonical SMILES |
CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
|
|||||
| InChI |
InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
|
|||||
| InChIKey |
TTZHDVOVKQGIBA-IQWMDFIBSA-N
|
|||||
| CAS Number |
CAS 1190307-88-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 529.5 | Topological Polar Surface Area | 153 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 11 | |||
| XLogP |
1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:85083
|
|||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | L-alanine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
| 3 | Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.